1. Generics Bulletin
  2. >>Products

Lannett To Launch Into Congested ADHD Market

Lines Up Latest Rival To Adderall XR

 
• By Aidan Fry

Lannett expects soon to launch a generic rival to Adderall XR following FDA approval for its partner SunGen. But the US generics specialist will face considerable competition.

Adderall
Lannett is poised to be the latest company offering a US generic rival to Adderall XR • Source: Shutterstock

Lannett expects “in the coming months” to start marketing in the US a generic version of Shire’s Adderall XR (dextroamphetamine saccharate/amphetamine aspartate/dextroamphetamine sulfate/amphetamine sulfate) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. But the US generics specialist will enter an already highly competitive market for the attention deficit hyperactivity disorder and narcolepsy drug.

In March this year, Lannett struck an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Roche Braces For Late 2026 Biosimilar Wave

 
• By Dean Rudge

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.